Iterum Therapeutics (ITRM) Cash & Current Investments (2017 - 2022)
Historic Cash & Current Investments for Iterum Therapeutics (ITRM) over the last 6 years, with Q3 2022 value amounting to $64.3 million.
- Iterum Therapeutics' Cash & Current Investments fell 2495.36% to $64.3 million in Q3 2022 from the same period last year, while for Sep 2022 it was $64.3 million, marking a year-over-year decrease of 2495.36%. This contributed to the annual value of $81.3 million for FY2021, which is 45837.45% up from last year.
- Iterum Therapeutics' Cash & Current Investments amounted to $64.3 million in Q3 2022, which was down 2495.36% from $68.9 million recorded in Q2 2022.
- In the past 5 years, Iterum Therapeutics' Cash & Current Investments registered a high of $135.3 million during Q2 2018, and its lowest value of $4.8 million during Q4 2019.
- Its 5-year average for Cash & Current Investments is $61.6 million, with a median of $69.2 million in 2019.
- Its Cash & Current Investments has fluctuated over the past 5 years, first tumbled by 9428.63% in 2019, then soared by 89317.5% in 2021.
- Quarter analysis of 5 years shows Iterum Therapeutics' Cash & Current Investments stood at $84.6 million in 2018, then tumbled by 94.29% to $4.8 million in 2019, then skyrocketed by 201.55% to $14.6 million in 2020, then surged by 458.37% to $81.3 million in 2021, then dropped by 20.92% to $64.3 million in 2022.
- Its Cash & Current Investments stands at $64.3 million for Q3 2022, versus $68.9 million for Q2 2022 and $75.3 million for Q1 2022.